Rhythmology Unit, Cardiology Institute, Pitié-Salpêtrière Hospital, Paris, France.
Europace. 2012 Feb;14(2):261-6. doi: 10.1093/europace/eur297. Epub 2011 Sep 13.
While in radiofrequency ablation for atrioventricular nodal reentry tachycardia (AVNRT) a residual jump and a single echo do not seem to substantially modify long-term results, in cryoablation procedures their effects are still under evaluation. The purpose of this study was to evaluate if a residual jump associated or not with an isolated echo is correlated with outcome.
acute successful slow pathway cryoablation for slow-fast AVNRT.
use of a 4 mm tip cryocatheter, no baseline elicitable jump or inducible AVNRT, and unwanted persistent first degree atrioventricular (AV) block at the end of the procedure. Cryoablation (-80°C × 4 min) was applied after successful cryomapping. Atrioventricular nodal reentry tachycardia inducibility was checked 30 min later on and off isoproterenol. Acute success was defined as AVNRT non-inducibility. Among 332 patients (pts) who had undergone cryoablation from May 2002 to March 2010 in our institutions, 245 of them fulfilled the entry criteria (173 women, mean age 41 ± 16 years, ineffective drugs 1.3 ± 1.1). A 7-Fr 6-mm tip cryocatheter (CryoCath®) was used in all cases. Baseline AV nodal effective refractory period (ERP) was 271 ± 55 ms, post-procedural ERP 331 ± 60 ms (P< 0.001), and the mean of the difference between baseline and post-procedural ERP 63 ± 38 ms. A/V ratio at successful site was 1 ± 0.4. Forty-four pts (18%) had a residual jump at the end of the procedure, and 14 of them had an associated single echo. Global cryoapplication time was 993 ± 797 s. During a follow-up of 40 ± 10 months, 43 pts (17.5%) had recurrences. At 12 months follow-up, actuarial rate of recurrence-free pts was 85% in the group without residual jump (201 pts), 63.3% with residual jump and no echo (30 pts), and 60.6% with residual jump associated with a single echo (P< 0.003 among groups). Univariate predictors of recurrences were persistence of a residual jump (P< 0.001) and total cryoapplication time (P< 0.02). In a multivariate model, only residual jump was independently correlated with recurrences (P< 0.01).
In patients undergoing AVNRT cryoablation, slow-pathway suppression is correlated with a better outcome. A single echo is associated with a recurrence risk similar to residual jump without echo. It may be suggested that pursuing a procedural endpoint up to slow pathway complete suppression may improve long-term success.
在射频消融房室结折返性心动过速(AVNRT)时,残留跳跃和单个回声似乎不会显著改变长期结果,但在冷冻消融手术中,其效果仍在评估中。本研究的目的是评估残留跳跃是否与单个回声相关,以及其与结果的关系。
急性冷冻消融成功治疗慢-快型房室结折返性心动过速。
使用 4 毫米尖端冷冻导管,无基线可诱发跳跃或可诱发房室结折返性心动过速,以及在手术结束时出现不可持续的第一度房室(AV)传导阻滞。冷冻消融(-80°C×4 分钟)在成功冷冻标测后应用。30 分钟后在停用异丙肾上腺素的情况下检查房室结折返性心动过速的可诱导性。急性成功定义为 AVNRT 不可诱导性。在 2002 年 5 月至 2010 年 3 月期间,在我们的机构中进行冷冻消融的 332 例患者中,245 例符合纳入标准(女性 173 例,平均年龄 41±16 岁,无效药物 1.3±1.1)。所有病例均使用 7Fr 6 毫米尖端冷冻导管(CryoCath®)。基线房室结有效不应期(ERP)为 271±55ms,术后 ERP 为 331±60ms(P<0.001),平均基线与术后 ERP 差值为 63±38ms。成功部位的 A/V 比值为 1±0.4。44 例(18%)在手术结束时出现残留跳跃,其中 14 例伴有单个回声。总的冷冻消融时间为 993±797s。在 40±10 个月的随访中,43 例(17.5%)出现复发。在 12 个月的随访中,无残留跳跃的 201 例患者中,无复发的患者的累积无复发率为 85%,无残留跳跃和无回声的 30 例患者为 63.3%,有残留跳跃和单个回声的 30 例患者为 60.6%(各组间 P<0.003)。复发的单因素预测因素是残留跳跃的持续存在(P<0.001)和总冷冻消融时间(P<0.02)。在多因素模型中,只有残留跳跃与复发独立相关(P<0.01)。
在接受房室结折返性心动过速冷冻消融的患者中,慢径路抑制与更好的结果相关。单个回声与无回声的残留跳跃相关的复发风险相似。可能表明,追求直至慢径完全抑制的手术终点可能会提高长期成功率。